Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer

Anouk K. M. Claessens; Frans L. G. Erdkamp; Marta Lopez-Yurda; Jeanette M. Bouma; Jeany M. Rademaker-Lakhai; Aafke H. Honkoop; Hiltje de Graaf; Vivianne C. G. Tjan-Heijnen; Monique E. M. M. Bos; Dutch Breast Canc Res Grp BOOG

doi:10.1080/0284186X.2020.1731923

Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer

Anouk K. M. Claessens, Frans L. G. Erdkamp, Marta Lopez-Yurda, Jeanette M. Bouma, Jeany M. Rademaker-Lakhai, Aafke H. Honkoop, Hiltje de Graaf, Vivianne C. G. Tjan-Heijnen, Monique E. M. M. Bos^*, Dutch Breast Canc Res Grp BOOG

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	713-722
Number of pages	10
Journal	Acta Oncologica
Volume	59
Issue number	6
DOIs	https://doi.org/10.1080/0284186X.2020.1731923
Publication status	Published - 2 Jun 2020

Keywords

METRONOMIC CHEMOTHERAPY
1ST-LINE TREATMENT
CLINICAL-OUTCOMES
TREATMENT PATTERNS
OPEN-LABEL
CYCLOPHOSPHAMIDE
CAPECITABINE
BENEFIT
BEVACIZUMAB
SURVIVAL

Access to Document

10.1080/0284186X.2020.1731923

Cite this

Claessens, A. K. M., Erdkamp, F. L. G., Lopez-Yurda, M., Bouma, J. M., Rademaker-Lakhai, J. M., Honkoop, A. H., de Graaf, H., Tjan-Heijnen, V. C. G., Bos, M. E. M. M., & Dutch Breast Canc Res Grp BOOG (2020). Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer. Acta Oncologica, 59(6), 713-722. https://doi.org/10.1080/0284186X.2020.1731923

Claessens, Anouk K. M. ; Erdkamp, Frans L. G. ; Lopez-Yurda, Marta ; Bouma, Jeanette M. ; Rademaker-Lakhai, Jeany M. ; Honkoop, Aafke H. ; de Graaf, Hiltje ; Tjan-Heijnen, Vivianne C. G. ; Bos, Monique E. M. M. ; Dutch Breast Canc Res Grp BOOG. / Secondary analyses of the randomized phase III Stop&Go study : efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer. In: Acta Oncologica. 2020 ; Vol. 59, No. 6. pp. 713-722.

@article{26c1e3fc992f464b9f55db5f1c715b0b,

title = "Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer",

keywords = "METRONOMIC CHEMOTHERAPY, 1ST-LINE TREATMENT, CLINICAL-OUTCOMES, TREATMENT PATTERNS, OPEN-LABEL, CYCLOPHOSPHAMIDE, CAPECITABINE, BENEFIT, BEVACIZUMAB, SURVIVAL",

author = "Claessens, {Anouk K. M.} and Erdkamp, {Frans L. G.} and Marta Lopez-Yurda and Bouma, {Jeanette M.} and Rademaker-Lakhai, {Jeany M.} and Honkoop, {Aafke H.} and {de Graaf}, Hiltje and Tjan-Heijnen, {Vivianne C. G.} and Bos, {Monique E. M. M.} and {Dutch Breast Canc Res Grp BOOG}",

year = "2020",

month = jun,

day = "2",

doi = "10.1080/0284186X.2020.1731923",

language = "English",

volume = "59",

pages = "713--722",

journal = "Acta Oncologica",

issn = "0284-186X",

publisher = "Routledge/Taylor & Francis Group",

number = "6",

}

Claessens, AKM, Erdkamp, FLG, Lopez-Yurda, M, Bouma, JM, Rademaker-Lakhai, JM, Honkoop, AH, de Graaf, H, Tjan-Heijnen, VCG, Bos, MEMM & Dutch Breast Canc Res Grp BOOG 2020, 'Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer', Acta Oncologica, vol. 59, no. 6, pp. 713-722. https://doi.org/10.1080/0284186X.2020.1731923

Secondary analyses of the randomized phase III Stop&Go study : efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer. / Claessens, Anouk K. M.; Erdkamp, Frans L. G.; Lopez-Yurda, Marta; Bouma, Jeanette M.; Rademaker-Lakhai, Jeany M.; Honkoop, Aafke H.; de Graaf, Hiltje; Tjan-Heijnen, Vivianne C. G.; Bos, Monique E. M. M.; Dutch Breast Canc Res Grp BOOG.

In: Acta Oncologica, Vol. 59, No. 6, 02.06.2020, p. 713-722.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Secondary analyses of the randomized phase III Stop&Go study

T2 - efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer

AU - Claessens, Anouk K. M.

AU - Erdkamp, Frans L. G.

AU - Lopez-Yurda, Marta

AU - Bouma, Jeanette M.

AU - Rademaker-Lakhai, Jeany M.

AU - Honkoop, Aafke H.

AU - de Graaf, Hiltje

AU - Tjan-Heijnen, Vivianne C. G.

AU - Bos, Monique E. M. M.

AU - Dutch Breast Canc Res Grp BOOG

PY - 2020/6/2

Y1 - 2020/6/2

KW - METRONOMIC CHEMOTHERAPY

KW - 1ST-LINE TREATMENT

KW - CLINICAL-OUTCOMES

KW - TREATMENT PATTERNS

KW - OPEN-LABEL

KW - CYCLOPHOSPHAMIDE

KW - CAPECITABINE

KW - BENEFIT

KW - BEVACIZUMAB

KW - SURVIVAL

U2 - 10.1080/0284186X.2020.1731923

DO - 10.1080/0284186X.2020.1731923

M3 - Article

VL - 59

SP - 713

EP - 722

JO - Acta Oncologica

JF - Acta Oncologica

SN - 0284-186X

IS - 6

ER -